Cel-Sci Corporation (CVM): Price and Financial Metrics

Cel-Sci Corporation (CVM): $0.63

0.02 (-2.67%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add CVM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#176 of 332

in industry

CVM Price/Volume Stats

Current price $0.63 52-week high $3.23
Prev. close $0.65 52-week low $0.54
Day low $0.61 Volume 533,600
Day high $0.65 Avg. volume 608,069
50-day MA $0.93 Dividend yield N/A
200-day MA $1.37 Market Cap 40.07M

CVM Stock Price Chart Interactive Chart >


Cel-Sci Corporation (CVM) Company Bio


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.


CVM Latest News Stream


Event/Time News Detail
Loading, please wait...

CVM Latest Social Stream


Loading social stream, please wait...

View Full CVM Social Stream

CVM Price Returns

1-mo -31.85%
3-mo -43.75%
6-mo -48.78%
1-year -73.19%
3-year -93.91%
5-year -91.80%
YTD -76.84%
2023 15.74%
2022 -66.90%
2021 -39.11%
2020 27.43%
2019 218.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!